Neuropace Inc.
Neuropace Inc. (NPCE): 3 pipeline candidates · ~32 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
31.8 months
D/E 5.84 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Neuropace Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$515.3M
Cash
$15.6M
Quarterly Burn
$5.9M
Runway
31.8 mo
Revenue
$22.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| neuropace rns system | — |
| rapport therapeutics product candidate | Preclinical |
| rns system | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
110
Total value held
$287.6M
| Holder | Shares | Value |
|---|---|---|
| polar capital holdings plc | 3,298,104 | $43.4M |
| morgan stanley | 2,566,839 | $33.8M |
| blackrock, inc. | 2,346,333 | $30.9M |
| vanguard capital management llc | 2,247,422 | $29.6M |
| orbimed advisors llc | 2,096,527 | $27.6M |
| driehaus capital management llc | 1,451,611 | $19.1M |
| deutsche bank ag\ | 932,090 | $12.3M |
| armistice capital, llc | 692,000 | $9.1M |
| geode capital management, llc | 618,119 | $8.1M |
| fmr llc | 553,529 | $7.3M |
Showing top 10 of 110 institutional holders of Neuropace Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Neuropace Inc.'s pipeline?
Neuropace Inc. (NPCE) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Neuropace Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Neuropace Inc. has approximately 31.8 months of cash runway.
What is Neuropace Inc.'s market capitalization?
Neuropace Inc.'s market capitalization is approximately $515.3M.
Who is the CEO of Neuropace Inc.?
Mr. Joel D. Becker is the chief executive officer of Neuropace Inc. (NPCE).
Get the full picture on Neuropace Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.